Solvent-Detergent Platelet Lysis for Growth Factor Recovery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current platelet-derived preparations lack standardization, leading to variability in growth factor content and clinical efficacy due to factors like platelet concentration, activation methods, and storage conditions, and pose risks of immune responses and infectious transmission.
Innovation Solution
A method to prepare a clottable, virally inactivated concentrate of platelet growth factors using a solvent and detergent treatment followed by oil extraction and chromatography, which increases recovery of key growth factors like PDGF, TGF-β, and EGF, and inactivates viruses and intact platelets, ensuring standardized and safe products.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If platelet concentrates are activated using conventional methods (thrombin or calcium chloride), then growth factors are released, but the preparations lack standardization and show variability in growth factor content and clinical efficacy
Solution Approach 1:
The patent applies parameter changes by modifying the activation conditions of platelets - using a specific pH range (6.0-9.0) and temperature range (2°C-50°C) during solvent/detergent treatment to optimize growth factor release while maintaining standardization. This controlled parameter approach ensures consistent manufacturing outcomes across different batches.
Solution Approach 2:
The patent introduces solvent and detergent as intermediary substances that facilitate the release of growth factors from platelets without requiring traditional activation methods. These intermediaries enable controlled extraction of growth factors while maintaining product standardization and reducing variability.
2Reliability
If platelet concentrates are used for therapeutic preparations, then growth factors are available for tissue regeneration, but there is risk of immune responses and infectious transmission
Solution Approach 1:
The patent converts the harmful presence of intact platelets and potential viral contaminants into a benefit by using solvent/detergent treatment that inactivates viruses and removes intact platelets while preserving and releasing growth factors. The treatment transforms a risky starting material into a safe therapeutic product.
Solution Approach 2:
The patent extracts and removes harmful components (intact platelets and viruses) from the platelet concentrate through solvent/detergent treatment and oil extraction, while retaining the beneficial growth factors. This selective removal eliminates immune response risks and infectious transmission while maintaining therapeutic efficacy.
3Object-affected harmful factors
If solvent and detergent treatment is applied to platelet concentrates, then viral inactivation and platelet lysis occur, but recovery of growth factors needs optimization
Solution Approach 1:
The patent optimizes growth factor recovery by carefully controlling parameters during solvent/detergent treatment - using specific concentrations (0.2-5% v/v), pH ranges (6.0-9.0), and temperature ranges (2°C-50°C). These parameter optimizations ensure maximum growth factor release while maintaining viral inactivation and platelet lysis effectiveness.
Solution Approach 2:
The patent uses oil as an intermediary substance to facilitate the extraction and removal of solvent/detergent from the platelet concentrate after treatment. This intermediary step helps recover growth factors while ensuring complete removal of potentially harmful solvent and detergent residues.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The method significantly enhances the recovery of platelet growth factors, reduces the risk of immune reactions and infectious transmission, and allows for the use of expired platelet stocks, providing a standardized and safe therapeutic product with enhanced efficacy.
Implementation Method 1
contacting a non-activated starting platelet concentrate with a solvent and/or a detergent
Implementation Method 2
inactivating viruses and intact platelets
Implementation Method 3
removing the solvent and/or the detergent by oil extraction
Implementation Method 4
chromatographic means
Implementation Method 5
trigger the coagulation cascade and the release of endogenous thrombin. The endogenous and exogenous thrombin also induce polymerisation of fibrinogen and formation of a fibrin-based biomaterial (a clot)
Data Source
Figure 1
Figure 2A~2D
Figure 3A~3C
AI summary
The present invention relates to a clottable concentrate of platelet growth factors for therapeutic and/or cosmetic use, preferably comprising the growth factors PDGF, TGF-ß, IGF, EGF, CTGF, bFGF and VEGF. In preferred embodiment said clottable concentrate of platelet growth factors does not induce blood cell-related transfusion reactions. The present invention also relates to a method for preparing a clottable concentrate of platelet growth factors according to the invention and comprising the steps of contacting a platelet concentrate with a solvent and/or a detergent, incubating said platelet concentrate with the solvent and/or detergent for a period of at least 5 minutes to 6 hours, at a pH maintained in a range from about 6.0 to about 9.0, and at a temperature within the range of from 2°C to 5O0C, preferably within the range of from 25°C to 45°C, and removing the solvent and/or the detergent by oil extraction and/or chromatographic means.